poisar

Stocks · News reference

Heartflow FFRCT Analysis Sustains 44% Reduction In Unnecessary Invasive Angiography At One Year, FUSION Trial Confirms

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HTFL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

    Heartflow announced one-year results from the independent FUSION trial showing its FFRCT Analysis reduced unnecessary invasive heart procedures by 44% when added to standard CCTA scans. The Dutch government-funded randomized controlled trial of 528 patients demonstrated that Heartflow's AI technology safely bridges diagnostic gaps in coronary artery disease evaluation, maintaining identical revascularization rates while significantly reducing diagnostic catheterizations.

    HTFL